GT200000078A - Profarmacos mutuos de amlodipino y atorvastatina. - Google Patents
Profarmacos mutuos de amlodipino y atorvastatina.Info
- Publication number
- GT200000078A GT200000078A GT200000078A GT200000078A GT200000078A GT 200000078 A GT200000078 A GT 200000078A GT 200000078 A GT200000078 A GT 200000078A GT 200000078 A GT200000078 A GT 200000078A GT 200000078 A GT200000078 A GT 200000078A
- Authority
- GT
- Guatemala
- Prior art keywords
- propharmaces
- amlodipino
- atorvastatin
- mutual
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
ESTA INVENCION SE REFIERE A LOS PROFARMACOS MUTUOS DE AMLODIPINO Y ATORVASTATINA (VER FORMULA I & II, RESPECTIVAMENTE) Y A LAS COMPOSICIONES FARMACEUTICAS DE LOS MISMOS. ESTA INVENCION TAMBIEN SE REFIERE A LOS PROCEDIMIENTOS PARA TRATAR ANGINA DE PECHO, LA ATEROSCLEROSIS Y LA HIPERTENSION Y LA HIPERLIPIDEMIA EN UN MAMIFERO MEDIANTE EL USO DE ESTOS PROFARMACOS Y COMPOSICIONES. ESTA INVENCION TAMBIEN SE REFIERE A LOS PROCEDIMIENTOS PARA TRATAR EL RIESGO CARDIACO EN UN MAMIFERO, INCLUYENDO HUMANOS, QUE PRESENTA SINTOMAS DE RIESGO CARDIACO MEDIANTE LA ADMINISTRACION DE ESTOS PROFARMACOS Y COMPOSICIONES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13660899P | 1999-05-27 | 1999-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000078A true GT200000078A (es) | 2001-11-16 |
Family
ID=22473579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000078A GT200000078A (es) | 1999-05-27 | 2000-05-25 | Profarmacos mutuos de amlodipino y atorvastatina. |
Country Status (41)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| GB0027410D0 (en) * | 2000-11-09 | 2000-12-27 | Pfizer Ltd | Mutual prodrug of amlodipine and atorvastatin |
| US6737430B2 (en) | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| KR100958552B1 (ko) * | 2001-06-11 | 2010-05-17 | 제노포트 인코포레이티드 | Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도 |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| DE10140421A1 (de) * | 2001-08-17 | 2003-03-06 | Bayer Ag | Neue Kombination |
| US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| CN102429882B (zh) | 2004-11-04 | 2015-03-25 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
| EP1909848A2 (en) * | 2005-08-01 | 2008-04-16 | PSivida Inc. | HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US8354116B2 (en) * | 2007-06-18 | 2013-01-15 | Biochemics, Inc. | Bifunctional synthetic molecules |
| JP4905738B2 (ja) | 2007-10-10 | 2012-03-28 | Ｎｏｋ株式会社 | アキュムレータ |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5155120A (en) | 1991-01-14 | 1992-10-13 | Pfizer Inc | Method for treating congestive heart failure |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. |
-
2000
- 2000-03-20 CA CA002375372A patent/CA2375372C/en not_active Expired - Fee Related
- 2000-03-20 CZ CZ20014229A patent/CZ20014229A3/cs unknown
- 2000-03-20 EA EA200101130A patent/EA200101130A1/ru unknown
- 2000-03-20 OA OA1200100312A patent/OA11950A/en unknown
- 2000-03-20 ES ES00911145T patent/ES2220426T3/es not_active Expired - Lifetime
- 2000-03-20 CN CN00808081A patent/CN1352640A/zh active Pending
- 2000-03-20 IL IL14594700A patent/IL145947A0/xx unknown
- 2000-03-20 SK SK1679-2001A patent/SK16792001A3/sk unknown
- 2000-03-20 HU HU0201433A patent/HUP0201433A2/hu unknown
- 2000-03-20 EE EEP200100631A patent/EE200100631A/xx unknown
- 2000-03-20 JP JP2000621364A patent/JP2003500487A/ja active Pending
- 2000-03-20 AP APAP/P/2001/002345A patent/AP2001002345A0/en unknown
- 2000-03-20 DE DE60011424T patent/DE60011424T2/de not_active Expired - Fee Related
- 2000-03-20 PL PL00353483A patent/PL353483A1/xx not_active Application Discontinuation
- 2000-03-20 AT AT00911145T patent/ATE268764T1/de not_active IP Right Cessation
- 2000-03-20 PT PT00911145T patent/PT1180102E/pt unknown
- 2000-03-20 TR TR2001/03391T patent/TR200103391T2/xx unknown
- 2000-03-20 EP EP00911145A patent/EP1180102B9/en not_active Expired - Lifetime
- 2000-03-20 KR KR1020017015185A patent/KR20020012247A/ko not_active Application Discontinuation
- 2000-03-20 MX MXPA01012125A patent/MXPA01012125A/es active IP Right Grant
- 2000-03-20 AU AU33139/00A patent/AU3313900A/en not_active Abandoned
- 2000-03-20 WO PCT/IB2000/000313 patent/WO2000073298A1/en active IP Right Grant
- 2000-03-20 DK DK00911145T patent/DK1180102T3/da active
- 2000-03-20 BR BR0011006-0A patent/BR0011006A/pt not_active IP Right Cessation
- 2000-05-17 HN HN2000000075A patent/HN2000000075A/es unknown
- 2000-05-19 PA PA20008495701A patent/PA8495701A1/es unknown
- 2000-05-24 US US09/577,561 patent/US6486182B1/en not_active Expired - Fee Related
- 2000-05-24 DZ DZ000092A patent/DZ3048A1/xx active
- 2000-05-24 MA MA25986A patent/MA26736A1/fr unknown
- 2000-05-24 TN TNTNSN00113A patent/TNSN00113A1/fr unknown
- 2000-05-24 CO CO00038315A patent/CO5170457A1/es not_active Application Discontinuation
- 2000-05-25 SV SV2000000082A patent/SV2002000082A/es not_active Application Discontinuation
- 2000-05-25 GT GT200000078A patent/GT200000078A/es unknown
- 2000-05-25 PE PE2000000498A patent/PE20010169A1/es not_active Application Discontinuation
- 2000-05-26 AR ARP000102581A patent/AR022344A1/es not_active Application Discontinuation
-
2001
- 2001-10-30 IS IS6135A patent/IS6135A/is unknown
- 2001-11-19 HR HR20010856A patent/HRP20010856A2/hr not_active Application Discontinuation
- 2001-11-26 NO NO20015756A patent/NO20015756L/no not_active Application Discontinuation
- 2001-11-26 ZA ZA200109691A patent/ZA200109691B/en unknown
- 2001-11-26 BG BG106149A patent/BG106149A/xx unknown
-
2002
- 2002-10-30 HK HK02107872.6A patent/HK1046282A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200000078A (es) | Profarmacos mutuos de amlodipino y atorvastatina. | |
| HN2002000154A (es) | Azaindoles | |
| HN2001000224A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. | |
| AR023423A1 (es) | Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos | |
| PA8557101A1 (es) | Benzimidazoles | |
| GT200000014A (es) | Derivados de quinolin - 2 - ona sustituidos con heteroarilo utiles como agentes anticancerigenos. | |
| CO4930259A1 (es) | Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen | |
| PT951474E (pt) | Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem | |
| CR7069A (es) | Derivados de pirazol para el tratamiento de vih | |
| CY1105705T1 (el) | Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6 | |
| ES2178037T3 (es) | Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen. | |
| UY28348A1 (es) | Compuestos novedosos | |
| UY27255A1 (es) | Derivados de mercaptoacetilamida , procedimiento para su preparacinn y su uso | |
| HN2002000300A (es) | Nuevos derivados de piperazina | |
| BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
| GT200000077A (es) | Sal mutua de amlodipino y atorvastatina | |
| GT199800134A (es) | Terapia de combinacion. | |
| PA8803201A1 (es) | Derivados acidos de cicloalquilamino | |
| HN2002000332A (es) | Sales de acido succinico de 5,7,14 triazatetraciclo (10. 3.1.02.11.04,9)-hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas | |
| GT200200158A (es) | Composiciones farmaceuticas de amlodipina y atorvastatina | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| PA8553701A1 (es) | Agentes antidiabeticos | |
| SE9801494D0 (sv) | Novel use | |
| CY1105798T1 (el) | Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων | |
| ES2175661T3 (es) | Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen. |